Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Reference-Cited by-同舟云学术

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions

Published:2024-06-03 Issue:2 Volume:60 Page:298-299
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chetwood J. D.¹²³^ORCID,Ding N. S.³⁴^ORCID

Affiliation:

1. Department of Medicine Concord Repatriation General Hospital Concord New South Wales Australia

2. Concord Clinical School University of Sydney Sydney New South Wales Australia

3. Department of Gastroenterology St Vincent's Hospital Melbourne Melbourne Victoria Australia

4. Department of Medicine University of Melbourne Melbourne Victoria Australia

Abstract

LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.18104.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18056

Reference5 articles.

1. Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

2. Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

3. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply;Alimentary Pharmacology & Therapeutics;2024-06-06